July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
AAV vector-mediated HLA-G expression to prevent corneal transplant rejection
Author Affiliations & Notes
  • Brian C Gilger
    Clinical Sciences, North Carolina State University, Raleigh, North Carolina, United States
  • Laura Conatser
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
    Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina, United States
  • Jacklyn H Salmon
    Clinical Sciences, North Carolina State University, Raleigh, North Carolina, United States
  • Richard Davis
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
  • Matthew Hirsch
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
    Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina, United States
  • Footnotes
    Commercial Relationships   Brian Gilger, Allergan (F), PoweredResearch (C), UNC/NCSU (P); Laura Conatser, None; Jacklyn Salmon, None; Richard Davis, None; Matthew Hirsch, NCTRACs (F), Tambid bio (C), UNC/NCSU (P)
  • Footnotes
    Support  North Carolina Translational Research Grant (MH, BG);
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3317. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brian C Gilger, Laura Conatser, Jacklyn H Salmon, Richard Davis, Matthew Hirsch; AAV vector-mediated HLA-G expression to prevent corneal transplant rejection. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3317.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Rejection rates following corneal transplantation (CT) remain high. Current treatments are limited in efficacy and elicit undesirable effects. We aim to develop an effective therapy to reduce corneal graft rejection using an adeno-associated virus (AAV) gene therapy designed to exploit the natural immune tolerance mechanism of human leukocyte antigen G (HLA-G).

Methods : Self-complementary AAV (scAAV) cassettes containing codon optimized HLA-G1 (transmembrane) or HLA-G5 (soluble) isoforms were validated in human cell culture with no indication of toxicity. Prior to CT, corneal donor buttons were incubated in a solution containing scAAV8G9-GFP (control) or scAAV8G9-HLA-G1/G5 for 1 hour. Rabbit or transplant grade human cornea were used as donor tissue. Central full-thickness CT was performed in one eye of normal New Zealand White rabbits. Ocular inflammation, corneal vascularization, corneal thickness, and rejection index (RI) were monitored after surgery. Once rejected, the rabbits were euthanized and eyes collected. Corneal sections were stained for GFP or HLA-G abundance. Serum collected before and after CT was analyzed for capsid neutralizing antibodies. Also, liver, brain, kidney, heart, gluteal muscle, and draining lymph nodes were harvested for assessment of vector biodistribution.

Results : In allotransplantation (rabbit donor to rabbit host), corneal vascularization and corneal graft edema were observed in GFP treated rabbit corneas by 10 days after surgery (RI > 6). HLA-G1/G5 treated rabbit CT remained clear with no corneal vascularization over 84 days. In xenotransplantation (human donor to rabbit host), HLA-G therapy significantly delayed rejection from 17.75+/-3.0 days after surgery (GFP) to 29.0+/-4.6 days (HLA-G) (p=0.015). Cornea sections showed high levels of HLA-G or GFP immunostaining throughout the stroma. Vector biodistribution was limited to the eye.

Conclusions : The data demonstrate ex vivo incubation of corneal grafts with scAAV8G9-HLA-G1/G5 prevented rejection of allograph CT and more importantly, delayed rejection in xenotransplantation. Validation is needed in other relevant models, but to prevent human to human, or animal to human CT rejection would be directly applicable to millions of patients worldwide with vision loss each year. Beyond the eye, successful execution of these studies would set precedence for use of ex vivo AAV-HLA-G in theoretically any tissue transplantation.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×